SBIR/STTR Research Award
To develop a customizable sample sparing
Award amount
$242,883Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Grace Bio-Labs, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- D5KJGKNYQKC7
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
Proposes to commercially develop a customizable sample sparingeasy to usecost effectiveand highly multiplexed protein microarray platform that will simultaneously measure multipleup toimmunoglobulin isotypes subtypes in the same sample across an entire landscape of multiple antigensThe platform is designed to define different effector functions for antibodies reactive with specifically mapped epitopesFor Phase Iwe have assembled an interdisciplinary team of experts from University of California IrvineIcahn School of Medicine at Mt SinaiNYand Grace Bio LabsIncto show proof of concept by creating a commercial assay to support research to develop a universal influenza virus vaccineThe platform combines conformationally correct antigens from conserved regions of NA and HA sub typesan epitope mapping planar microarray platformand inexpensive transportable array imager employing quantum nanocrystal conjugated secondary antibody cocktailsboth designed specifically for antibody profilingCommercialization will be predicated on successfully validating the array data vsELISAand demonstrating robust QC processes and long term stability of conformational epitopesSuccess in Phase I will lay the groundwork for the developmentin Phase IIof a broadly applicable solution for infectious disease specialists and epidemiologistsparticularly in endemic disease areas where such analytics will have the greatest impact
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients